Comparing Organon & Co. (NYSE:OGN) and Unicycive Therapeutics (NASDAQ:UNCY)

Organon & Co. (NYSE:OGN – Get Free Report) and Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, earnings, valuation and dividends.

Earnings and Valuation

This table compares Organon & Co. and Unicycive Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Organon & Co. $6.22 billion 0.59 $187.00 million $0.76 18.28
Unicycive Therapeutics $680,000.00 145.39 -$26.56 million ($1.75) -2.03

Organon & Co. has higher revenue and earnings than Unicycive Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Organon & Co. and Unicycive Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Organon & Co. 3.49% 82.06% 6.03%
Unicycive Therapeutics N/A -91.50% -61.47%

Insider and Institutional Ownership

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk and Volatility

Organon & Co. has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 1.91, suggesting that its stock price is 91% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Organon & Co. and Unicycive Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Organon & Co. 1 4 0 0 1.80
Unicycive Therapeutics 1 1 5 0 2.57

Organon & Co. presently has a consensus target price of $12.00, suggesting a potential downside of 13.64%. Unicycive Therapeutics has a consensus target price of $18.25, suggesting a potential upside of 414.08%. Given Unicycive Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Unicycive Therapeutics is more favorable than Organon & Co..

Summary

Organon & Co. beats Unicycive Therapeutics on 8 of the 14 factors compared between the two stocks.

About Organon & Co.

(Get Free Report)

Organon & Co. is a global health care company focused on women’s health, biosimilars and established medicines. It develops and markets prescription medicines and other health products for patients and health care professionals. Its women’s health portfolio includes contraceptive and fertility products, while its biosimilars business offers biologic medicines in areas such as immunology and oncology. The company also sells established medicines across several therapeutic areas, including cardiovascular health, respiratory conditions and dermatology.

About Unicycive Therapeutics

(Get Free Report)

Unicycive Therapeutics is a biopharmaceutical company focused on developing treatments for kidney diseases. Its lead program, oxylanthanum carbonate (OLC), is an oral phosphate binder being developed to help manage hyperphosphatemia, or elevated blood phosphate levels, in people with chronic kidney disease, including patients receiving dialysis. The company is also developing UNI-494, an investigational small-molecule therapy for acute kidney injury. These programs reflect Unicycive’s focus on conditions for which treatment options may be limited.

Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.